Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Phase 1/2 Active not recruiting 28 enrolled Nelum Corp Agenus Inc. · collab Apices Soluciones S.L. · collab

NaSingle-groupOpen-labelTreatment

Summary

In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of the signaling pathway of Hedgehog and an immunotherapy drug able of blocking the CTLA-4 receptor.

Timeline

Start: 2021-09-01
Primary completion: 2025-04
Completion: 2025-04

Publications

McAndrews KM, Mahadevan KK, Kalluri R. Mouse Models to Evaluate the Functional Role of the Tumor Microenvironment in Cancer Progression and Therapy Responses. Cold Spring Harb Perspect Med. 2024 Jul 1;14(7):a041411. doi: 10.1101/cshperspect.a041411.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NLM-001	Unknown	—	—
Subject	Zalifrelimab	Monoclonal antibody	—	—
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	125 mg/m2	Intravenous

Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications